May 27, 2010
Will a global subsidy for Artemisinin-based combination treatments (ACTs) discourage the use of less effective drugs and monotherapies and delay the development of artemisinin resistance?
What we found
A global subsidy for ACTs would prolong the effective life of artemisinin as well as other antimalarials by delaying the development of artemisinin resistance.
Why it matters
A subsidy for ACTs – even partial – would slow the development of artemisinin resistance and save lives, and a delay in implementing a subsidy (even by two years) would lead to faster resistance to ACTs.